Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Randomised, Open-label, Multi-centre Study to Assess the Impact on Disease Control, Safety, Patient and Clinician Experience of Changing Patients With Advanced Prostate Cancer From a 3-monthly LHRH Agonist to 6-monthly Injections of Decapeptyl® SR 22.5 MG

NCT01673984 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT01673984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01673984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Randomised, Open-label, Multi-centre Study to Assess the Impact on Disease Control, Safety, Patient and Clinician Experience of Changing Patients With Advanced Prostate Cancer From a 3-monthly LHRH Agonist to 6-monthly Injections of Decapeptyl® SR 22.5 MG
Lead sponsor
Ipsen
Phase
Phase 4
Overall status
Terminated
Start date
August 31, 2012
Completion date
February 28, 2014
Enrollment
27 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer